您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Clinafloxacin(hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Clinafloxacin(hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Clinafloxacin(hydrochloride)图片
CAS NO:105956-99-8
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
Clinafloxacin (hydrochloride) (AM 1091 hydrochloride) 是一种有效的广谱氟喹诺酮类抗生素,在体外对革兰氏阳性菌、革兰氏阴性菌和厌氧菌具有抑制活性。
Cas No.105956-99-8
别名克林沙星盐酸盐; AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride
化学名7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Canonical SMILESOC(C1=CN(C2CC2)C3=C(Cl)C(N4CCC(N)C4)=C(F)C=C3C1=O)=O.Cl
分子式C17H17ClFN3O3o HCl
分子量402.3
溶解度≤1mg/ml in methanol(heated)
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Clinafloxacin is a broad-spectrum antibiotic of the quinolone carboxylic acid category that inhibits both DNA gyrase and topoisomerase IV dually in Streptococcus pneumonia. Clinafloxacin, a fluoroquinolone, is currently in development for oral and intravenous therapy of serious infections.

In selected volunteer subjects and patients, after the administration of oral and intravenous doses of racemic drug, the clinafloxacin showed a broad-spectrum antibiotic of the quinolone carboxylic acid category. The absorption of the clinafloxacin enantiomer was rapid after oral 400 mg dose and 400 mg intravenous dose of racemic drug [1]. Clinafloxacin showed high activity against S. pneumoniae 7785 with the MIC value of 0.125 μg/ml. Clinafloxacin showed potent broad-spectrum in vitro activity against gram-positive, gram-negative, and anaerobic pathogens [2]. Clinafloxacin has been identified as the most active fluoroquinolone against S. pneumoniae compared to grepafloxacin, levofloxacin, ofloxacin, sparfloxacin, and trovafloxacin and is currently being evaluated as an antipneumococcal agent [3].

References:
[1].  Humphrey G H, Shapiro M A, Randinitis E J, et al. Pharmacokinetics of clinafloxacin enantiomers in humans[J]. The Journal of Clinical Pharmacology, 1999, 39(11): 1143-1150.
[2].  Pan X S, Fisher L M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae[J]. Antimicrobial Agents and Chemotherapy, 1998, 42(11): 2810-2816.
[3].  Jorgensen J H, Weigel L M, Swenson J M, et al. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae[J]. Antimicrobial agents and chemotherapy, 2000, 44(11): 2962-2968.